Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015978 | 1.00 | LMNA (0.40) | LMNAOPRM1OPRD1SLC6A3SLC6A4 | |
| SCHEMBL25530903 | 1.00 | LMNA (0.40) | LMNAOPRM1OPRD1SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL25215294 | 0.97 | LMNA (0.39) | LMNAOPRM1OPRD1SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL19926062 | 0.97 | LMNA (0.39) | LMNAOPRM1OPRD1SLC6A3SLC6A4 | |
| SCHEMBL2836174 | 0.97 | LMNA (0.37) | LMNAOPRM1OPRD1SLC6A3SLC6A4 | |
| SCHEMBL5022562 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL34473465 | 0.90 | LMNA (0.32) | LMNA | |
| SCHEMBL2843814 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL34474173 | 0.83 | OPRM1 (0.31) | OPRM1 | |
| Trifluoroacetic Acid SCHEMBL3757015 | 0.81 | LMNA (0.41) | LMNAOPRM1OPRD1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | claimed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | claimed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | claimed |
| CN-109843379-A | Substituted ureas and methods of making and using the same | 梅比斯发现公司 | 2019-06-04 | — | — | CN | claimed |
| WO-2018045229-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-03-08 | — | — | WO | claimed |
| US-9556117-B2 | Indole carboxamide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-31 | — | — | US | claimed |
| EP-2935211-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-09 | — | — | EP | claimed |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-03 | — | — | US | claimed |
| US-12503451-B2 | 2-arylthiazole derivative or salt thereof, preparation method therefor, and pharmaceutical composition comprising same | HEXAPHARMATEC CO., LTD. (KR) | 2025-12-23 | — | — | US | disclosed |
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4463452-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-4140989-B1 | 2-ARYLTHIAZOLE DERIVATIVE OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HEXAPHARMATEC CO LTD (KR) | 2024-07-17 | — | — | EP | disclosed |
| WO-2007129195-A2 | 4-PYRIMIDINE-5-AMINO-PYRAZOLE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-7126027-B2 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | AKZO NOBEL N.V. (NL) | 2006-10-24 | — | — | US | disclosed |
| US-20040242685-A1 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | N.V. ORGANON (NL) | 2004-12-02 | — | — | US | disclosed |
| EP-1419138-A1 | N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES | Akzo Nobel (NL) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003010132-A1 | N-[(1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003010132-A1 | N-[(1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503451-B2 | 2-arylthiazole derivative or salt thereof, preparation method therefor, and pharmaceutical composition comprising same | WEE2, WEE1, NOTUM | LMNA 4153/4885OPRM1 3903/4885OPRD1 2781/4885 |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | LMNA 2785/4885OPRM1 237/4885OPRD1 112/4885 |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | UMPS, METTL3, UTS2R | LMNA 1718/4885OPRM1 178/4885OPRD1 868/4885 |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | LMNA 1344/4885OPRM1 2962/4885OPRD1 3596/4885 |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | LMNA 1718/4885OPRM1 178/4885OPRD1 868/4885 |
| US-20040242685-A1 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | SLC1A2, SLC6A1, KCNT2 | LMNA 3106/4885OPRM1 351/4885OPRD1 516/4885 |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | LMNA 1344/4885OPRM1 2962/4885OPRD1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.